МУЛЬТИФОРМНАЯ ГЛИОБЛАСТОМА: ПАТОГЕНЕЗ И МОЛЕКУЛЯРНЫЕ МАРКЕРЫ
PDF

Ключевые слова

МУЛЬТИФОРМНАЯ ГЛИОБЛАСТОМА
МОЛЕКУЛЯРНЫЕ МАРКЕРЫ
ОНКОГЕННЫЕ МУТАЦИИ
ЭПИГЕНЕТИЧЕСКИЕ ИЗМЕНЕНИЯ

Аннотация

Мультиформная глиобластома (GBM) - наиболее распространенная и инвазивная низкодифференцированная опухоль мозга, характеризующаяся практически 100 %-ным рецидивированием и неблагоприятным прогнозом для пациентов. Цель настоящего обзора - анализ исследований и экспериментальных результатов последних лет (базы данных Scopus, Web of Science, Pubmed), касающихся характерных для глиобластомы соматических мутаций, аберрантной регуляции экспрессии генов сигнальных путей, в т.ч., EGFR, TGFß, а также маркеров прогрессирования GBM. Отдельно обсуждаются молекулярно-генетические субтипы глиобластом и результаты NGS-исследований.
https://doi.org/10.37469/0507-3758-2017-63-5-695-702
PDF

Библиографические ссылки

Al-Mayhani M.T., Grenfell R., Narita M. et al. NG2 expression in glioblastoma identifies an actively proliferating population with an aggressive molecular signature // Neuro Oncol. - 2011. - Vol. 13. - № 8. - P. 830-845.

Arif S.H., Pandith A.A., Bhat A.R. et al. EGFR and PTEN gene mutation status in glioblastoma patients and their prognostic impact on patient's survival // J. Carcinog. Mutagen. - 2015. - Vol. 6. - P. 218.

Armstrong T.S., Prabhu S., Aldape K. et al. A case of soft tissue metastasis from glioblastoma and review of the literature // J. Neurooncol. - 2011. - Vol. 103. - P. 167- 172.

Balakrishnan A., Bleeker F.E., Lamba S. et al. Novel somatic and germline mutations in cancer candidate genes in glioblastoma, melanoma, and pancreatic carcinoma // Cancer Res. - 2007. - Vol. 67. - P. 3545-3550.

Brennan C.W., Verhaak R.G.W., McKenna A. et al. The somatic genomic landscape of glioblastoma // Cell. - 2013. - Vol. 155. - P. 462-477.

Chamberlain M.C. Bevacizumab for the treatment of recurrent glioblastoma // Clin. Med. Insights Oncol. - 2011. - Vol. 5. - P. 117-129.

Chandran U.R., Luthra S., Santana-Santos L. et al. Gene expression profiling distinguishes proneural glioma stem cells from mesenchymal glioma stem cells // Genomics Data. - 2015. - Vol. 5. - P. 333-336.

Cohen A.L., Colman H. Glioma biology and molecular markers. In: Current understanding and treatment of gliomas. Cancer Treatment and Research. - 2015. - Vol. 163. - P. 15-30. Eds Raizer J., Parsa A. Springer International Publishing.

Combs S.E., Rieken S., Wick W. et al. Prognostic significance of IDH-1 and MGMT in patients with glioblastoma: One step forward, and one step back? // Radiat. Oncol. - 2011. - Vol. 6. - P. 115.

Diamandis P., Ferrer-Luna R., Huang R.Y et al. Case report: next generation sequencing identifies a NAB2-STAT6 fusion in glioblastoma // Diagn. Pathol. - 2016. - Vol. 11. - P. 13.

Fang X., Yoon J.G., Li L. et al. The SOX2 response program in glioblastoma multiforme: an integrated ChIP-seq, expression microarray, and microRNA analysis // BMC Genomics. - 2011. - Vol. 12. - P. 11.

Fontebasso A.M., Schwartzentruber J., Khuong-Quang D.A. et al. Mutations in SETD2 and genes affecting his-tone H3K36 methylation target hemispheric high-grade gliomas // Acta Neuropathol. - 2013. - Vol. 125. - P. 659-669.

Fontebasso A.M., Papillon-Cavanagh S., Schwartzentruber J. et al. Recurrent somatic mutations in ACVR1 in pediatric midline high-grade astrocytoma // Nat. Genet. - 2014. - Vol. 46. - P. 462-466.

Hadjipanayis C.G., Van Meir E.G. Brain cancer propagating cells: biology, genetics and targeted therapies // Trends Mol. Med. - 2009. - Vol. 14. - P. 519-530.

Hodges T.R., Choi B.D., Bigner D.D. et al. Isocitrate dehydrogenase 1 (IDH1): what it means to the neurosurgeon // J. Neurosurg. - 2013. - Vol. 118. - № 6. - P. 1176-1180.

Holdhoff M., Yovino S., Boadu O., Grossman S.A. Blood-based biomarkers for malignant gliomas // J. Neurooncol. - 2013. - Vol. 113. - P. 345-352.

Ikushima H., Todo T., Ino Y et al. Glioma-initiating cells retain their tumorigenicity through integration of the Sox axis and Oct4 protein // J. Biol. Chem. - 2011. - Vol. 286. - P. 41434-41441.

Iwamoto F.M., Hormigo A. Unveiling YKL-40, from serum marker to target therapy in glioblastoma // Front. Oncol. - 2014. - Vol. 4. - P. 90.

Joseph J.V., Balasubramaniyan V., Walenkamp A., Kruyt F.A.E. TGF-ß as a therapeutic target in high grade gliomas - promises and challenges // Biochem. Pharmacol. - 2013. Vol. 85. - P. 478-485.

Kierulf-Vieira K.S., Sandberg C.J., Grieg Z. et al. Wnt inhibition is dysregulated in gliomas and its re-establishment inhibits proliferation and tumor sphere formation // Exp. Cell Res. - 2016. - Vol. 340. - P. 53-61.

Kruczyk M., Przanowski P., Dabrowski M. et al. Integration of genome-wide of STAT3 binding and epigenetic modification mapping with transcriptome reveals novel Stat3 target genes in glioma cells // Biochim. Biophys. Acta. - 2014. - Vol. 1839. - P. 1341-1350.

Lee H.K., Bier A., Cazacu S. et al. MicroRNA-145 is down-regulated in glial tumors and regulates glioma cell migration by targeting connective tissue growth factor // Plos One. - 2013. - Vol. 8. - e54652.

Lee J.C., Vivanco I., Beroukhim R. et al. Epidermal growth factor receptor activation in glioblastoma through novel missense mutations in the extracellular domain // PLoS Med. - 2006. - Vol. 3. - e485.

Lindsay A., Holthouse D., Robbins P., Knuckey N. Spinal leptomeningeal metastases following glioblastoma multiforme treated with radiotherapy // J. Clin. Neurosci. - 2002. - Vol. 9. - P. 725- 728.

Lo H.W., Cao X., Zhu H., Ali-Osman F. Constitutively activated STAT3 frequently coexpresses with epidermal growth factor receptor in high-grade gliomas and targeting STAT3 sensitizes them to Iressa and alkylators // Clin. Cancer Res. - 2008. - Vol. 14. - P. 6042-6054.

Lovejoy C.A., Li W., Reisenweber S. et al. Loss of ATRX, genome instability, and an altered DNA damage response are hallmarks of the alternative lengthening of telomeres pathway // PLoS genet. - 2012. - Vol. 8. - e1002772.

Marziali G., Signore M., Buccarelli M. et al. Metabolic/proteomic signature defines two glioblastoma subtypes with different clinical outcome // Nat. Sci. Rep. - 2016. - Vol. 6. - P. 21557.

Maslehaty H., Cordovi S., Hefti M. Symptomatic spinal metastases of intracranial glioblastoma: clinical characteristics and pathomechanism relating to GFAP expression // J. Neurooncol. - 2011. - Vol. 101. - P. 329 -333.

Morokoff A., Ng W., Gogos A., Kaye A.H. Molecular subtypes, stem cells and heterogeneity: Implications for personalised therapy in glioma // J. Clin. Neurosci. - 2015. - Vol. 22. - P. 1219-1226.

Nicolaidis S. Biomarkers of glioblastoma multiforme // Metabolism. - 2015. - Vol. 64. - S22-7.

Ohgaki H., Kleihues P. Genetic pathways to primary and secondary glioblastoma // Am. J. Pathol. - 2007. - Vol. 170. - P. 1445-1453.

Ohgaki H., Kleihues P. The definition of primary and secondary glioblastoma // Clin. Cancer Res. - 2013. - Vol. 19. - № 4. - P. 764-772.

Olar A., Sulman E.P. Molecular markers in low-grade glioma - toward tumor reclassification // Semin. Radiat. Oncol. - 2015. - Vol. 25. - P. 155-163.

Paff M., Alexandru-Abrams D., Hsu F.P.K, Bota D.A. The evolution of the EGFRvIII (rindopepimut) immunotherapy for glioblastoma multiforme patients // Hum. Vaccin. Immunother. - 2014. - Vol. 10. - P. 3322-3331.

Patel R., Shervington A. Telomerase and DNA repair in glioma // Biochim. Biophys. Acta. - 2009. - Vol. 1792. - P. 275-279.

Rani S.B., Rathod S.S., Karthik S. et al. MiR-145 functions as a tumor-suppressive RNA by targeting Sox9 and adducin 3 in human glioma cells // Neuro Oncol. - 2013. - Vol. 15. - P. 1302-1316.

Reilly E.B., Phillips A.C., Buchanan F.G. et al. Characterization of ABT-806, a humanized tumor-specific anti-EG-FR moloclonal antibody // Mol. Cancer Ther. - 2015. - Vol. 14. - P. 1141-1151.

Rheinbay E., Suva M.L., Gillespie S.M. et al. An aberrant transcription factor network essential for Wnt signaling and stem cell maintenance in glioblastoma // Cell Rep. - 2013. - Vol. 3. - P. 1567-1579.

Rivera A.L., Pelloski C.E., Sulman E., Aldape K. Prognostic and predictive markers in glioma and other neuroepithelial tumors // Curr. Probl. Cancer. - 2008. - Vol. 32. - P. 97-123.

Swartz A.M., Li Q.J., Sampson J.H. Rindopepimut: A promising immunotherapeutic for the treatment of glioblastoma multiforme // Immunotherapy. - 2014. - Vol. 6. - P. 679-690.

Taylor T.E., Furnari F.B., Cavenee W.B. Targeting EGFR for treatment of glioblastoma: molecular basis to overcome resistance // Curr. Cancer Drug Targets. - 2012. - Vol. 12. - P. 197-209.

Van Meir E.G., Hadjipanayis C.G., Norden A.D. et al. Exciting new advances in neuro-oncology: the avenue to a cure for malignant glioma // CA-Cancer J. Clin. - 2010. - Vol. 60. - P. 166-193.

Verhaak R.G.W., Hoadley K.A., Purdom E. et al. An integrated genomic analysis identifies clinically relevant subtypes of glioblastoma characterized by abnormalities in PDGFRA, IDH1, EGFR and NF1 // Cancer Cell. - 2010. - Vol. 17. - № 1. - P. 98.

Wang J., Su H-K., Zhao H-F. et al. Progress in the application of molecular biomarkers in gliomas // Biochem. Biophys. Res. Comm. - 2015. - Vol. 465. - P. 1-4.

Wang Z-H., Zhang Q-S., Duan Y-L. et al. TGF-ß induced miR-132 enhances the activation of TGF-ß signaling through inhibiting SMAD7 expression in glioma cells // Biochem. Biophys. Res. Commun. - 2015. - Vol. 463. - P. 187-192.

Wang Z-L., Zhang C-B., Cai J-Q. et al. Integrated analysis of genome-wide DNA methylation, gene expression and protein expression profiles in molecular subtypes of WHo II-IV gliomas // J. Exp. Clin. Cancer Res. - 2015. - Vol. 34. - P. 127.

Witt H., Mack S.C., Ryzhova M. et al. Delineation of two clinically and molecularly distinct subgroups of posterior fossa ependymoma // Cancer Cell. - 2011. - Vol. 20. - P. 143-157.

Xu Y-R., Yang W-X. soX-mediated crosstalk during the progression of tumorigenesis // semin. Cell Dev. Biol. - 2016. - Vol. 63. - P. 23-34.

Yadavilli s., Hwang E.I., Packer R.J., Nazarian J. The role of NG2 proteoglycan in glioma // Transl. oncol. - 2016. - Vol. 9. - P 57-63.

Yang J., Liao D., Wang Z. et al. Mammalian target of rapamycin signaling pathway contributes to glioma progression and patients' prognosis // J. surg. Res. - 2011. - Vol. 168. - P 97-102.

Yang Y, Shao N., Luo G. et al. Mutations of PTEN gene in gliomas correlate to tumor differentiation and short-term survival rate // Anticancer Res. - 2010. - Vol. 30. - P 981-985.

Zhang D.F., Li X.G., su L.J., Meng Q.L. Expression of activin A and follistatin in glioblastoma and their effects on U87 in vitro // J. Int. Med. Res. - 2010. - Vol. 38. - № 4. - P. 1343-1353.

Лицензия Creative Commons

Это произведение доступно по лицензии Creative Commons «Attribution-NonCommercial-NoDerivatives» («Атрибуция — Некоммерческое использование — Без производных произведений») 4.0 Всемирная.

Copyright (c) 2017 Олег Кит, Дмитрий Водолажский, Елена Франциянц, Светлана Панина, Э. Расторгуев, Д. Поркшеян